SCShuai Chen

Shuai Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuai Chen has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predicting cerebrospinal fluid α-synuclein seed amplification assay positivity in borderline hyposmia

    by Yu-Xiang Jiao, Pei-Wen Han, Peng-Bo Yang, Shuang He, Xiao Liu, Chen-Hong Li, Jie-Wen Zhang, Shuai Chen

  • Open Access

    Preserved olfaction unmasks choroid plexus–related cognitive risk in Parkinson’s disease

    by Shuang He, Yu-Xiang Jiao, Pei-Wen Han, Hao-Han Zhang, Kai Ma, Xi-Jin Wang, Jie-Wen Zhang, Shuai Chen

    Background: Choroid plexus volume (CPV) has been associated with cognitive impairment in Parkinson’s disease (PD), particularly frontal-executive dysfunction, whereas olfactory dysfunction is linked to cognitive deterioration and may reflect greater α-synuclein involvement. Whether olfactory status modifies the association between CPV and cognitive outcomes remains unclear. Methods: We analyzed 718 participants with early-stage PD followed for up to 10 years. Baseline CPV was derived from structural MRI. Hyposmia was defined as an age- and sex-adjusted University of Pennsylvania Smell Identification Test percentile ≤ 15. Kaplan–Meier and multivariable Cox models were used to examine incident cognitive milestone (CogM), including a CPV × olfactory status interaction. CPV was standardized to 1-SD units. Multiple sensitivity analyses assessed robustness. Results: Among 709 participants with olfactory data, 502 (70.8%) had hyposmia. Ten-year CogM-free survival was 59.4%. The primary Cox analysis included 680 participants and 173 CogM events. Among participants with normosmia, each 1-SD increase in CPV was associated with higher CogM risk (HR = 1.63, 95% CI 1.20–2.22, P = 0.002). Hyposmia was associated with higher CogM risk at the mean CPV level (HR = 1.91, 95% CI 1.23–2.97, P = 0.004). The CPV × hyposmia interaction was significant (HR = 0.62, 95% CI 0.43–0.88, P = 0.008); the CPV association was absent in participants with hyposmia (HR = 1.01, 95% CI 0.83–1.22, P = 0.950). Findings were consistent across sensitivity analyses. Conclusion: Olfactory status modified the association between CPV and cognitive outcomes in early PD. Larger CPV was associated with higher CogM risk in participants with preserved olfaction, but not in those with hyposmia. These findings warrant validation in independent cohorts.

  • Striatal DAT and disease progression in Parkinson's disease: New evidence from autonomic dysfunction

    by Haohan Zhang, Rong Li, Yuxiang Jiao, Yuxin Niu, Xiaodi Hao, Hitoshi Shimada, Yu Shen, Kai Ma, Shuai Chen, Jiewen Zhang


  • Open Access

    Clinical, neuroimaging, and biomarker profiling of four Alzheimer’s disease pedigrees caused by pathogenic APP variants

    by Jie-Wen Zhang, Rong Li, Yu-Xin Niu, Si-Yuan Liu, Chen-Hong Li, Xiao-Di Hao, Sheng-Hui Wang, Shuai Chen, Feng-Yu Wang

    Current understanding of the fluid biomarker profile in early-onset Alzheimer’s disease (EOAD) associated with pathogenic APP variants remains limite

  • Open Access

    CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

    by Jing‐Yu Shao, Rong Li, Yu‐Xiang Jiao, Kai Ma, Hong‐Qi Yang, Zheng‐Yu Sun, Jie‐Wen Zhang, Shuai Chen

    Background: Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD. Objective: We therefore examined associations of CSF 3,4‐dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3,4‐dihydroxyphenylglycol (DOPEG), and 5‐hydroxyindoleacetic acid (5‐HIAA) with baseline Montreal Cognitive Assessment (MoCA) scores and with longitudinal rates of change. Methods: Ninety‐five patients with early PD and fifty‐six demographically matched healthy controls (HCs) were included from the Parkinson's Progression Markers Initiative cohort. Baseline CSF concentrations of monoamine metabolites were measured by liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS). In PD patients, multivariable linear regression and linear mixed‐effects models were used to evaluate the cross‐sectional and longitudinal associations, respectively, between baseline CSF metabolites and MoCA scores. To facilitate comparison, the levels of monoamine metabolites were converted into Z‐scores to attain standardized β coefficients. Results: Compared with HCs, PD patients had lower baseline CSF concentrations of DOPAC, HVA, and 5‐HIAA. After adjustment for relevant covariates, any standardized CSF metabolite was not associated with baseline MoCA scores. Lower baseline CSF DOPAC and HVA were significantly associated with more rapid cognitive decline over time (z‐DOPAC: β = 0.17, p < 0.001; z‐HVA: β = 0.14, p = 0.009). Neither DOPEG nor 5‐HIAA was associated with longitudinal cognitive decline. Conclusions: Taken together, our results indicated that baseline CSF DOPAC and HVA may serve as promising longitudinal predictors of cognitive decline in patients with PD.

  • Relationship between striatal dopaminergic depletion and cognitive milestone in Parkinson's disease: A comprehensive analysis of striatal subregions, laterality, and nonlinear relationships

    by Jing-Yu Shao, Yu Shen, Rong Li, Xue-Feng Xiang, Chen-Hong Li, Zheng-Yu Sun, Shuai Chen, Jie-Wen Zhang

    Background: In Parkinson's disease (PD), striatal dopaminergic degeneration follows a posterior-anterior gradient, with asymmetric involvement and an exponential decline in early disease stages. Previous investigations of the relationship between striatal dopamine transporter (DAT) availability and cognitive impairment in PD have been insufficient, especially in longitudinal studies. Objective: To examine the longitudinal associations between baseline DAT availability and cognitive milestone (CogM) from the perspectives of striatal subregions, laterality, and nonlinear threshold effects. Methods: A total of 467 patients with early, sporadic PD without CogM and with available striatal DAT data at baseline were included from the Parkinson's Progression Markers Initiative database. Annual follow-up data over eight years were analyzed. Standard multivariable Cox and restricted cubic spline (RCS) Cox models were used to assess the associations between DAT uptake and CogM. Two-piecewise Cox regression was used to explore potential threshold effects. Results: The 8-year cumulative probability of being CogM-free was 66.0%. In multivariable Cox models, DAT uptake in the ipsilateral, but not contralateral, caudate and putamen was inversely associated with CogM. RCS Cox models revealed a linear negative association for the ipsilateral caudate, but an L-shaped association for the ipsilateral putamen. Two-piecewise Cox regression identified a threshold effect at a DAT uptake of 1.04 in the ipsilateral putamen, below which the risk of CogM increased significantly. Conclusions: Baseline ipsilateral caudate DAT uptake shows a linear inverse relationship with CogM, highlighting its potential as an early predictive biomarker. The L-shaped association observed for ipsilateral putamen DAT warrants further mechanistic investigation.


  • A predictive model for longitudinal cognitive subtypes in Parkinson's disease

    by Meng-Yun Wang, Ran Xin, Jing-Yu Shao, Sheng-Hui Wang, Hong-Qi Yang, Hong-Ju Zhang, Jie-Wen Zhang, Shuai Chen

    Background Longitudinal cognitive changes in Parkinson’s disease (PD) exhibit considerable heterogeneity.Predicting cognitive trajectories in early PD patients can improve prognostic counseling and guide clinical trials. Methods This study included 337 early PD patients with 6-year follow-up in the Parkinson's Progression Markers Initiative (PPMI) database.Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) to identify subtypes of longitudinal cognitive trajectories, and a nomogram predictive model was constructed using baseline clinical variables. Results The 337 PD patients had a mean age of 61.0 years, mean disease duration of 0.55 years, and mean MoCA score of 27.1 points. Latent class mixed models (LCMM) identified two longitudinal cognitive subtypes: cognitive stable (276 cases, 81.9%) and cognitivel deteriorating (61 cases, 18.1%). The cognitively deteriorating subtype presented poorer baseline cognition, older age, and more severe motor and non-motor symptoms. On biomarkers, the cognitively deteriorating subtype revealed higher serum NFL levels and lower mean striatum DAT uptake. Six baseline clinical variables (age, Letter Number Sequencing score, Symbol Digit Modalities Test score, Benton Judgment of Line Orientation Test score, Hopkins Verbal Learning Test-Revised score, and REM Sleep Behavior Disorder) were selected to construct the nomogram predictive model which achieved an AUC of 0.92.The calibration curve demonstrated high consistency between predicted and observed probabilities.The predictive model has potential utility in disease-modifying clinical trials by pre-screening patients at high risk for cognitive deterioration. Conclusion This study identified two longitudinal cognitive subtypes: cognitive stable and cognitive deterioration within 6-year follow-up, and eighteen percent of early PD patients shared the cognitive deterioration subtype The predictive model, incorporating six baseline variables could estimate the risk of longitudinal cognitive deterioration in PD.


  • Multitracer PET/CT Findings in a Case of Behavioral Variant Frontotemporal Dementia With Parkinsonism

    by Shuai Chen, Chang Fu, Jing-Yu Shao, Jun-Ling Xu, Jie-Wen Zhang

    S: We report the clinical and multimodal PET/CT manifestations in a patient with behavioral variant frontotemporal dementia and parkinsonism. The 18F-FDG PET scan revealed hypometabolism in the left supratentorial cortex. The 18F-fluorodopa PET scan demonstrated decreased uptake in the bilateral striatum, most prominent in the head of caudate nucleus. The 18F-florbetapir PET scan indicated an absence of β-amyloid deposition, whereas the 18F-flortaucipir PET scan showed uptake in the left hemisphere neocortex. The clinical presentation and asymmetric neuroimaging features supported the underlying frontotemporal lobar degeneration-tau pathology.

  • A prediction model for the walking and balance milestone in Parkinson's disease

    by Jing-Yu Shao, Meng-Yun Wang, Rong Li, Hong-Qi Yang, Xin-Xin He, Jie-Wen Zhang, Shuai Chen